Health insurance, Medicare supplement benefits and prescription drugs provisions modifications
SF2477 is a broad health insurance and prescription drug transparency bill. It makes several changes to Minnesota insurance law, including Medicare supplement coverage rules, guaranteed renewal and discontinuation standards for individual health plans, HMO cancellation and replacement coverage requirements, and health plan network adequacy standards. It also updates hospital closure and service-reduction notice and hearing requirements, revises the composition and meeting rules for the Health Equity Advisory and Leadership (HEAL) Council, and changes terminology and reporting obligations in several health care statutes.
A major portion of the bill expands prescription drug pricing disclosure. It strengthens reporting by drug manufacturers, pharmacies, pharmacy benefit managers, and wholesale drug distributors for drugs identified as being of “substantial public interest,” and it requires the Department of Health to publicly post more drug price information. The bill also expands and refines reporting for the federal 340B drug program, including acquisition costs, revenues, contract pharmacy payments, and payer-type breakdowns, with certain data reported to the legislature in aggregate form. It further modifies uniform explanation of benefits requirements and related administrative standards for health care reimbursement documents.
The bill would amend multiple chapters of Minnesota Statutes governing insurance, health care reporting, hospital regulation, and public health administration. In practice, it would give the commissioner of commerce and the commissioner of health more oversight over Medicare supplement pricing, individual market plan discontinuations, network adequacy waivers, hospital service reductions, and prescription drug reporting. It would also create new or expanded disclosure duties for manufacturers, pharmacies, PBMs, wholesalers, and 340B covered entities, while classifying some submitted data as nonpublic and limiting public posting where trade secret protections apply.
The available record does not include committee transcripts or recorded votes, so there is no direct evidence of debate or floor sentiment in the materials provided. Based on the bill text, the overall policy direction appears consumer- and transparency-oriented, with a focus on protecting enrollees, increasing public access to drug pricing information, and improving notice before major hospital or coverage changes. The bill’s structure suggests broad regulatory support for oversight and disclosure rather than deregulation.
The most likely points of contention are the expanded reporting and public posting requirements for prescription drug pricing and 340B-related financial data, which may raise concerns about administrative burden, confidentiality, and trade secret protection for manufacturers, pharmacies, PBMs, wholesalers, and hospitals. Another potential area of dispute is the commissioner’s authority to disapprove discontinuation of a particular individual health plan if it is not in policyholders’ best interest, which could be viewed as stronger consumer protection but also as a constraint on carrier flexibility. Hospital notice and public hearing requirements, especially the 182-day advance notice and mandatory public participation for closures or service reductions, may also be controversial among hospital operators.